FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2314280003> ?p ?o ?g. }

• W2314280003 abstract "Purpose: Inhibition of the FAK-VEGFR-3 interaction by the small molecule inhibitor chloropyramine hydrochloride (CFAK-C4) has been shown to reduce tumor growth both alone and synergistically with doxorubicin and gemcitabine in an animal tumor model. A multiple dose study of CFAK-C4 in dogs was investigated to gain knowledge in estimating a first in man dose. Methods: CFAK-C4 was given to two female and two male dogs as an IV infusion at 1.25 or 2.5 mg/kg for five minutes, on three consecutive days, days 1, 2 and 3. Single- and multiple-dose PK samples were collected on days 1 and 3 of dosing. Plasma samples were collected at 0.5, 1, 2, 4, 8, and 24 hours post-dose. CFAK-C4 concentrations were determined using LC-MS/MS, with a LLOQ of 2.5 pg/ml. Noncompartmental PK analysis was performed using WinNonlin (Pharsight, version 5.3). Results: The mean CFAK-C4 plasma concentration-time profiles revealed a biexponential decline of drug following IV infusion, independent of day of dosing. The median (range) half-life was 3.42 hours (2.75-4.06 hours) and 3.79 (3.5-5.0) on days 1 and 3 following administration of 1.25 mg/kg CFAK-C4. At the 2.5 mg/kg dose level, the median half-life was similar. The median (range) Cmax of 1.25 mg/kg CFAK-C4 was determined to be 75 ng/ml (41-87 ng/ml) on day 1 and 99 ng/ml (84-102 ng/ml) on day 3. After the 2.5 mg/kg dose the Cmax was 185 ng/ml (165-244 ng/ml) and 171 ng/ml (153-181 ng/ml) on days 1 and 3 respectively. The AUC0-24 at the 1.25 mg/kg dose level was similar on both days 1 and 3 with a median (range) of 167 ng*hr/ml (117-231 ng*hr/ml) and 178 ng*hr/ml (170-194 ng*hr/ml), respectively. The AUC0-24 was also similar after the 2.5 mg/kg dose on days 1 and 3 with a median (range) of 447 ng*hr/ml (434-495 ng*hr/ml) and 406 ng*hr/ml (400-460 ng*hr/ml), respectively. The median (range) clearance for dose 1.25 mg/kg was 7.46 L/hr/kg (5.36-10.59 L/hr/kg) on day 1 and 6.47 L/hr/kg (6.07-6.91L/hr/kg) on day 3. For the 2.5 mg/kg dose level, the median (range) clearance was slightly lower compared with the 1.25 mg/kg dose, with values of 5.48 L/hr/kg (5.02-5.66 L/hr/kg) and 5.85 L/hr/kg (5.04-5.93 L/hr/kg) on days 1 and 3, respectively. Utilizing allometric scaling techniques of PK parameters from mice and dogs for CFAK-C4, the estimated human PK parameters for volume of distribution, clearance and half-life were 1695 L, 126 L/hr, and 9.34 hours, respectively. Subsequently, using a no observable adverse event level (NOAEL) of 44.5 mg/kg IP for mice and a NOAEL of 2.5 mg/kg IV for dog, the human starting dose (assuming a 70 kg human) would be a daily dose of 25 mg and 10 mg based on mouse or dog, respectively. Given that dogs are the most sensitive species, 10 mg daily is the suggested first dose in man for CFAK-C4. Conclusions: These results demonstrate that CFAK-C4 has linear kinetics and that no accumulation of drug occurs after multiple dosing. Allometric scaling of mouse and dog data allowed for the estimation of the first in man dose of CFAK-C4. Citation Format: Allison Gaudy, John Wilton, Leslie Curtin, Elena Kurenova, Sandra Buitrago, William Cance, Gerald Fetterly. Pharmacokinetic analysis of CFAK-C4 in dogs and estimation of first dose in man. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3372. doi:10.1158/1538-7445.AM2013-3372" @default.
• W2314280003 created "2016-06-24" @default.
• W2314280003 creator A5004485473 @default.
• W2314280003 creator A5021355807 @default.
• W2314280003 creator A5024475539 @default.
• W2314280003 creator A5038285212 @default.
• W2314280003 creator A5049273530 @default.
• W2314280003 creator A5052141297 @default.
• W2314280003 creator A5062284417 @default.
• W2314280003 date "2013-04-15" @default.
• W2314280003 modified "2023-09-27" @default.
• W2314280003 title "Abstract 3372: Pharmacokinetic analysis of CFAK-C4 in dogs and estimation of first dose in man." @default.
• W2314280003 doi "https://doi.org/10.1158/1538-7445.am2013-3372" @default.
• W2314280003 hasPublicationYear "2013" @default.
• W2314280003 type Work @default.
• W2314280003 sameAs 2314280003 @default.
• W2314280003 citedByCount "0" @default.
• W2314280003 crossrefType "proceedings-article" @default.
• W2314280003 hasAuthorship W2314280003A5004485473 @default.
• W2314280003 hasAuthorship W2314280003A5021355807 @default.
• W2314280003 hasAuthorship W2314280003A5024475539 @default.
• W2314280003 hasAuthorship W2314280003A5038285212 @default.
• W2314280003 hasAuthorship W2314280003A5049273530 @default.
• W2314280003 hasAuthorship W2314280003A5052141297 @default.
• W2314280003 hasAuthorship W2314280003A5062284417 @default.
• W2314280003 hasConcept C112705442 @default.
• W2314280003 hasConcept C121608353 @default.
• W2314280003 hasConcept C126322002 @default.
• W2314280003 hasConcept C140793950 @default.
• W2314280003 hasConcept C185592680 @default.
• W2314280003 hasConcept C22979827 @default.
• W2314280003 hasConcept C2777288759 @default.
• W2314280003 hasConcept C2780258809 @default.
• W2314280003 hasConcept C3020079912 @default.
• W2314280003 hasConcept C71924100 @default.
• W2314280003 hasConcept C86803240 @default.
• W2314280003 hasConcept C98274493 @default.
• W2314280003 hasConceptScore W2314280003C112705442 @default.
• W2314280003 hasConceptScore W2314280003C121608353 @default.
• W2314280003 hasConceptScore W2314280003C126322002 @default.
• W2314280003 hasConceptScore W2314280003C140793950 @default.
• W2314280003 hasConceptScore W2314280003C185592680 @default.
• W2314280003 hasConceptScore W2314280003C22979827 @default.
• W2314280003 hasConceptScore W2314280003C2777288759 @default.
• W2314280003 hasConceptScore W2314280003C2780258809 @default.
• W2314280003 hasConceptScore W2314280003C3020079912 @default.
• W2314280003 hasConceptScore W2314280003C71924100 @default.
• W2314280003 hasConceptScore W2314280003C86803240 @default.
• W2314280003 hasConceptScore W2314280003C98274493 @default.
• W2314280003 hasLocation W23142800031 @default.
• W2314280003 hasOpenAccess W2314280003 @default.
• W2314280003 hasPrimaryLocation W23142800031 @default.
• W2314280003 hasRelatedWork W1581058556 @default.
• W2314280003 hasRelatedWork W2007591678 @default.
• W2314280003 hasRelatedWork W2015804711 @default.
• W2314280003 hasRelatedWork W202919892 @default.
• W2314280003 hasRelatedWork W2072701103 @default.
• W2314280003 hasRelatedWork W2073892563 @default.
• W2314280003 hasRelatedWork W2074149075 @default.
• W2314280003 hasRelatedWork W2109907236 @default.
• W2314280003 hasRelatedWork W2325445208 @default.
• W2314280003 hasRelatedWork W2332619527 @default.
• W2314280003 hasRelatedWork W2336385083 @default.
• W2314280003 hasRelatedWork W2349400912 @default.
• W2314280003 hasRelatedWork W2396552334 @default.
• W2314280003 hasRelatedWork W2399686612 @default.
• W2314280003 hasRelatedWork W2418513456 @default.
• W2314280003 hasRelatedWork W2517764491 @default.
• W2314280003 hasRelatedWork W3015034761 @default.
• W2314280003 hasRelatedWork W3209881455 @default.
• W2314280003 hasRelatedWork W73993321 @default.
• W2314280003 hasRelatedWork W2407278108 @default.
• W2314280003 isParatext "false" @default.
• W2314280003 isRetracted "false" @default.
• W2314280003 magId "2314280003" @default.
• W2314280003 workType "article" @default.